The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Selected publications for Tommy Andersson

Selected publications for Tommy Andersson

  • OSMAN J, BELLAMONDO K, LIU Q, ANDERSSON T* & SJÖLANDER A*. The WNT5A agonist Foxy5 reduces the number of colonic cancer stem cells in a xenograph mouse model of human colonic cancer. Anticancer Research 39:1719-1728, 2019. * These authors contributed equally to this study
  • MOHAPATRA P, PRASAD CP and ANDERSSON T. Combination therapy targeting the elevated interleukin-6 level reduces invasive migration of BRAF inhibitor-resistant melanoma cells. Molecular Oncology, doi.org/10.1002/1878-0261.12433, 2018. 
  • PRASAD CP. MANCHANDA M, MOHAPATRA P and ANDERSSON T. Wnt5a as a therapeutic target in breast cancer. Cancer and Metastasis Reviews, 37(4), 767-778; doi: 10.1007/s10555-018-9760-y, 2018.
  • CANESIN G, EVANS-AXELSSON S, HELLSTEN R, KRZYZANOWSKA A, PRASAD CP, BJARTELL A and ANDERSSON T. Treatment with the Wnt5a-mimicking peptide Foxy5 effectively reduces the metastatic spread of Wnt5a-low prostate cancer cells in an orthotopic mouse model. PLoS ONE  doi.org/10.1371/journal.pone.084418, 2017.
  • PRGOMET Z, ANDERSSON T and LINDBERG P. Higher expression of WNT5A in oral squamous cell carcinoma compared to dysplasia and oral mucosa with a normal appearance. Eur. J. Oral Sciences 125:237-246, 2017.
  • PRASAD CP, SÖDERGREN K and ANDERSSON T. Reduced production and uptake of lactate are essential for the ability of WNT5A signaling to inhibit breast cancer cell migration and invasion. Oncotarget  8:71471-71488, 2017.
  • PRASAD CP, CHAURASIYA SK, GUILMAIN W, and ANDERSSON T. WNT5A signaling impairs breast cancer cell migration and invasion via mechanisms independent of the epithelial-mesenchymal transition.
    J. Experimental & Clinical Cancer Research 35(1):144 (DOI 10.1186/s13046-016-0421-0), 2016.
  • MEHDAWI LM, PRASAD CP, EHRNSTRÖM R, ANDERSSON T and SJÖLANDER A. Non-canonical WNT5A signaling up-regulates the expression of the tumor suppressor 15-PGDH via JNK1 and induces differentiation of colon cancer cells. Molecular Oncology 10(9):1415-1429, 2016.
  • LINNSKOG R, MOHAPATRA P, FARNAZ M, PRASAD CP and Andersson t. Demonstration of a WNT5A-IL-6 positive feedback loop in melanoma cells: Dual interference of this loop more effectively impairs melanoma cell invasion.Oncotarget  7:37790-37802, 2016 (Doi: 10.18632/oncotarget.9332).
  •  OSMAN J, BELLAMONDO K, LIU Q, ANDERSSON T* & SJÖLANDER A*. The WNT5A agonist Foxy5 reduces the number of colonic cancer stem cells in a xenograph mouse model of human colonic cancer. Anticancer Research 39:1719-1728, 2019. * These authors contributed equally to this study.
  • MOHAPATRA P, PRASAD CP and ANDERSSON T. Combination therapy targeting the elevated interleukin-6 level reduces invasive migration of BRAF inhibitor-resistant melanoma cells.
    Molecular Oncology, doi.org/10.1002/1878-0261.12433, 2018.
  • PRASAD CP. MANCHANDA M, MOHAPATRA P and ANDERSSON T. Wnt5a as a therapeutic target in breast cancer.
    Cancer and Metastasis Reviews, 37(4), 767-778; doi: 10.1007/s10555-018-9760-y, 2018.
  • CANESIN G, EVANS-AXELSSON S, HELLSTEN R, KRZYZANOWSKA A, PRASAD CP, BJARTELL A and ANDERSSON T. Treatment with the Wnt5a-mimicking peptide Foxy5 effectively reduces the metastatic spread of Wnt5a-low prostate cancer cells in an orthotopic mouse model. PLoS ONE  doi.org/10.1371/journal.pone.084418, 2017.
  • PRGOMET Z, ANDERSSON T and LINDBERG P. Higher expression of WNT5A in oral squamous cell carcinoma compared to dysplasia and oral mucosa with a normal appearance. Eur. J. Oral Sciences 125:237-246, 2017.
  • PRASAD CP, SÖDERGREN K and ANDERSSON T. Reduced production and uptake of lactate are essential for the ability of WNT5A signaling to inhibit breast cancer cell migration and invasion. Oncotarget  8:71471-71488, 2017
  • PRASAD CP, CHAURASIYA SK, GUILMAIN W, and ANDERSSON T. WNT5A signaling impairs breast cancer cell migration and invasion via mechanisms independent of the epithelial-mesenchymal transition. 
    J. Experimental & Clinical Cancer Research 35(1):144 (DOI 10.1186/s13046-016-0421-0), 2016.
  • MEHDAWI LM, PRASAD CP, EHRNSTRÖM R, ANDERSSON T and SJÖLANDER A. Non-canonical WNT5A signaling up-regulates the expression of the tumor suppressor 15-PGDH via JNK1 and induces differentiation of colon cancer cells. Molecular Oncology 10(9):1415-1429, 2016.
  • LINNSKOG R, MOHAPATRA P, FARNAZ M, PRASAD CP and Andersson t. Demonstration of a WNT5A-IL-6 positive feedback loop in melanoma cells: Dual interference of this loop more effectively impairs melanoma cell invasion. Oncotarget  7:37790-37802, 2016 (Doi: 10.18632/oncotarget.9332).
  • Prasad, P.C. Mohapatra, P. Andersson, T. Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?. Cancers 2015, 7, 1900-1924, 2015.
  • Linnskog, R. Jönsson, G. Axelsson, L. Prasad, P. C. Andersson, T. Interleukin-6 drives melanoma cell motility through p38a -MAPK-dependent up-regulation of WNT5A expression. Molecular Oncology 8 (2014) 1365 - 1378, 2014.
  • Sand-Dejmek L., Ehrnström R.,Berglund P., Andersson T., Ryden L. The Prognostic Significance of Wnt-5a Expression in Primary Breast Cancer Is Extended to Premenopausal Women. Plos One, 2013, Vol. 8 Issue 8, 2013.
  • Prasad P. C, Chaurasiya K. S, Axelsson L., Andersson T. WNT-5A triggers Cdc42 activation leading to an ERK1/2 dependent decrease in MMP9 activity and invasive migration of breast cancer cells. Molecular Oncology 7 (2013) 870 - 883, 2013.
  • Scherwood, V. Chaurasiya, K.S. Ekström J.E. Guilmain W. Liu, Q. Koechk, T. Brown, K. Hansson K. Agnarsdóttir, M. Bergqvist, M. Jirström, K. Ponten, F. James, P. Andersson, T. WNT5A-mediated β-catenin-independent signalling is a novel regulator of cancer cell metabolism. Carcinogenesis vol.35 no.4 pp.784 - 794, 2014, 2013.
  • Jenei, V. Sherwood, B. Howlin, J. Linnskog, R. Säfholm, A. Axelsson, L. Andersson, T.
    A t-butyloxycarbonyl-modified Wnt5a-derived hexapeptide functions as a potent antagonist of Wnt5a-dependent melanoma cell invasion. Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19473-8, 2009.
  • Hansen, C. Howlin, J. Tenghlm, A. Dyachok, O. Vogel, F. W. Nairn, C.A. Greengard, P. Andersson, T. Wnt-5a-induced Phosphorylation of DARPP-32 Inhibits Breast Cancer Cell Migration in a CREB-dependent Manner. The Journal of Biological Chemistry VOL. 284, NO. 40. pp. 27533-27543, 2009.
  • Säfholm, A. Tuomela, J. Rosenkvist, J. Dejmek, J. Härkönen, P. Andersson, T. The Wnt-5a-Derived Hexapeptide Foxy-5 Inhibits Breast Cancer Metastasis In vivo by Targeting Cell Motility.  American Association for Cancer Research. Clin Cancer Res 2008;14(20), 2008. 
  • Säfholm, A. Leandersson, K. Dejmek, J. Kamp Nielsen, C. Villoutreix, B. and Andersson, T.
    A formylated hexapeptide ligand mimics the ability of Wnt-5a to impair migration of humman breast epithelial cells. Journal of Biological Chemistry 281;2740-2749, 2006.
 

Cell and experimental pathology

Page manager: diana [dot] vaduva [at] med [dot] lu [dot] se | 6 Apr 2021